Germany's drug shortages leave patients struggling in 2025 despite reforms
Drug shortages persist in German pharmacies throughout 2025, with over 1,500 shortage reports documenting 1,041 distinct supply bottlenecks. Patients and healthcare providers grapple with ongoing challenges due to these persistent issues. Antipsychotics are particularly affected, with 173 shortage reports impacting 151 products and lasting an average of 230 days. Antidepressants follow closely, with 130 reports affecting 126 products and lasting around 107 days on average. Lipid-lowering agents also face significant supply issues, with 89 reports covering 80 products and lasting about 156 days. Antibiotics, though less affected, still see 85 reports across 78 products, averaging 122 days of disruption. Shortages of salbutamol and antiepileptic drugs are raising particular concern due to the lack of readily available alternatives. Despite the 2023 Shortages Act, health insurers report no structural improvements in drug supply stability. In response, stakeholders are proposing an early-warning system to flag major production failures in Asia, alerting German supply chains promptly and potentially preventing shortages before they reach patients. The ongoing shortages highlight the fragility of Germany's drug supply chain, particularly for critical medications like antipsychotics and antibiotics. An early-warning system could mitigate future disruptions by addressing production issues at their source, preventing patients from facing delays in accessing essential treatments.
Read also:
- India's Agriculture Minister Reviews Sector Progress Amid Heavy Rains, Crop Areas Up
- Over 1.7M in Baden-Württemberg at Poverty Risk, Emmendingen's Housing Crisis Urgent
- Life Expectancy Soars, But Youth Suicide and Substance Abuse Pose Concern
- Cyprus, Kuwait Strengthen Strategic Partnership with Upcoming Ministerial Meeting
